<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>1 Introduction | thesis.utf8</title>
  <meta name="description" content="" />
  <meta name="generator" content="bookdown 0.16 and GitBook 2.6.7" />

  <meta property="og:title" content="1 Introduction | thesis.utf8" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="1 Introduction | thesis.utf8" />
  
  
  




  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="index.html"/>
<link rel="next" href="chapter2.html"/>
<script src="libs/jquery-2.2.3/jquery.min.js"></script>
<script src="libs/elevate-section-attrs-2.0/elevate-section-attrs.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />









<script src="libs/kePrint-0.0.1/kePrint.js"></script>


<style type="text/css">
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
  { counter-reset: source-line 0; }
pre.numberSource code > span
  { position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
  { content: counter(source-line);
    position: relative; left: -1em; text-align: right; vertical-align: baseline;
    border: none; display: inline-block;
    -webkit-touch-callout: none; -webkit-user-select: none;
    -khtml-user-select: none; -moz-user-select: none;
    -ms-user-select: none; user-select: none;
    padding: 0 4px; width: 4em;
    color: #aaaaaa;
  }
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa;  padding-left: 4px; }
div.sourceCode
  {   }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } /* Alert */
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } /* Annotation */
code span.at { color: #7d9029; } /* Attribute */
code span.bn { color: #40a070; } /* BaseN */
code span.bu { } /* BuiltIn */
code span.cf { color: #007020; font-weight: bold; } /* ControlFlow */
code span.ch { color: #4070a0; } /* Char */
code span.cn { color: #880000; } /* Constant */
code span.co { color: #60a0b0; font-style: italic; } /* Comment */
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } /* CommentVar */
code span.do { color: #ba2121; font-style: italic; } /* Documentation */
code span.dt { color: #902000; } /* DataType */
code span.dv { color: #40a070; } /* DecVal */
code span.er { color: #ff0000; font-weight: bold; } /* Error */
code span.ex { } /* Extension */
code span.fl { color: #40a070; } /* Float */
code span.fu { color: #06287e; } /* Function */
code span.im { } /* Import */
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } /* Information */
code span.kw { color: #007020; font-weight: bold; } /* Keyword */
code span.op { color: #666666; } /* Operator */
code span.ot { color: #007020; } /* Other */
code span.pp { color: #bc7a00; } /* Preprocessor */
code span.sc { color: #4070a0; } /* SpecialChar */
code span.ss { color: #bb6688; } /* SpecialString */
code span.st { color: #4070a0; } /* String */
code span.va { color: #19177c; } /* Variable */
code span.vs { color: #4070a0; } /* VerbatimString */
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } /* Warning */
</style>

</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./"></a></li>
<li class="divider"></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Preface</a>
<ul>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html#abstract"><i class="fa fa-check"></i>Abstract</a></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html#acknowledgements"><i class="fa fa-check"></i>Acknowledgements</a></li>
</ul></li>
<li class="chapter" data-level="1" data-path="chapter1.html"><a href="chapter1.html"><i class="fa fa-check"></i><b>1</b> Introduction</a>
<ul>
<li><a href="chapter1.html#increased-adiposity-and-associtions-with-disease"><em>Increased adiposity and associtions with disease</em></a></li>
<li class="chapter" data-level="1.1" data-path="chapter1.html"><a href="chapter1.html#background"><i class="fa fa-check"></i><b>1.1</b> Background</a></li>
<li class="chapter" data-level="1.2" data-path="chapter1.html"><a href="chapter1.html#adipose-tissue"><i class="fa fa-check"></i><b>1.2</b> Adipose tissue</a>
<ul>
<li class="chapter" data-level="1.2.1" data-path="chapter1.html"><a href="chapter1.html#energy-fat-storage"><i class="fa fa-check"></i><b>1.2.1</b> Energy (fat) storage</a></li>
<li class="chapter" data-level="1.2.2" data-path="chapter1.html"><a href="chapter1.html#insulation-and-cushioning"><i class="fa fa-check"></i><b>1.2.2</b> Insulation and cushioning</a></li>
<li class="chapter" data-level="1.2.3" data-path="chapter1.html"><a href="chapter1.html#signalling"><i class="fa fa-check"></i><b>1.2.3</b> Signalling</a></li>
<li class="chapter" data-level="1.2.4" data-path="chapter1.html"><a href="chapter1.html#genetics"><i class="fa fa-check"></i><b>1.2.4</b> Genetics</a></li>
</ul></li>
<li class="chapter" data-level="1.3" data-path="chapter1.html"><a href="chapter1.html#BMI-disease"><i class="fa fa-check"></i><b>1.3</b> BMI and disease</a></li>
<li class="chapter" data-level="1.4" data-path="chapter1.html"><a href="chapter1.html#additional-measures"><i class="fa fa-check"></i><b>1.4</b> Additional measures</a>
<ul>
<li class="chapter" data-level="1.4.1" data-path="chapter1.html"><a href="chapter1.html#whr"><i class="fa fa-check"></i><b>1.4.1</b> WHR</a></li>
<li class="chapter" data-level="1.4.2" data-path="chapter1.html"><a href="chapter1.html#bf"><i class="fa fa-check"></i><b>1.4.2</b> BF%</a></li>
</ul></li>
<li class="chapter" data-level="1.5" data-path="chapter1.html"><a href="chapter1.html#why-does-more-fat-mean-more-disease"><i class="fa fa-check"></i><b>1.5</b> Why does more fat mean more disease?!?!?!</a>
<ul>
<li class="chapter" data-level="1.5.1" data-path="chapter1.html"><a href="chapter1.html#causal-analysis-set-up-sr-and-future-work"><i class="fa fa-check"></i><b>1.5.1</b> Causal analysis (set up SR and future work)</a></li>
</ul></li>
<li class="chapter" data-level="1.6" data-path="chapter1.html"><a href="chapter1.html#metabolites-are-gr8"><i class="fa fa-check"></i><b>1.6</b> metabolites are gr8</a></li>
<li class="chapter" data-level="1.7" data-path="chapter1.html"><a href="chapter1.html#aims"><i class="fa fa-check"></i><b>1.7</b> Aims</a></li>
<li class="chapter" data-level="1.8" data-path="chapter1.html"><a href="chapter1.html#objectives"><i class="fa fa-check"></i><b>1.8</b> Objectives</a></li>
<li class="chapter" data-level="1.9" data-path="chapter1.html"><a href="chapter1.html#notes-for-writing"><i class="fa fa-check"></i><b>1.9</b> Notes for writing</a></li>
<li class="chapter" data-level="1.10" data-path="chapter1.html"><a href="chapter1.html#conclusion"><i class="fa fa-check"></i><b>1.10</b> Conclusion</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="chapter2.html"><a href="chapter2.html"><i class="fa fa-check"></i><b>2</b> Systematic review</a></li>
<li class="chapter" data-level="3" data-path="chapter3.html"><a href="chapter3.html"><i class="fa fa-check"></i><b>3</b> Instrumentation</a>
<ul>
<li><a href="chapter3.html#instrumenting-measures-of-increased-adiposity"><em>Instrumenting measures of increased adiposity</em></a>
<ul>
<li class="chapter" data-level="3.0.1" data-path="chapter3.html"><a href="chapter3.html#correlation-of-measures-of-increased-adiposity"><i class="fa fa-check"></i><b>3.0.1</b> Correlation of measures of increased adiposity</a></li>
</ul></li>
<li class="chapter" data-level="3.1" data-path="chapter3.html"><a href="chapter3.html#supplementary-information"><i class="fa fa-check"></i><b>3.1</b> Supplementary Information</a>
<ul>
<li class="chapter" data-level="3.1.1" data-path="chapter3.html"><a href="chapter3.html#supp-alspac"><i class="fa fa-check"></i><b>3.1.1</b> ALSPAC Overview</a></li>
<li class="chapter" data-level="3.1.2" data-path="chapter3.html"><a href="chapter3.html#supp-biobank"><i class="fa fa-check"></i><b>3.1.2</b> UK Biobank Overview</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="4" data-path="chapter4.html"><a href="chapter4.html"><i class="fa fa-check"></i><b>4</b> Observational analysis of metabolites</a></li>
<li class="chapter" data-level="5" data-path="chapter5.html"><a href="chapter5.html"><i class="fa fa-check"></i><b>5</b> Mendelian randomization analysis: stage 1</a></li>
<li class="chapter" data-level="6" data-path="chapter6.html"><a href="chapter6.html"><i class="fa fa-check"></i><b>6</b> Data visualisation</a>
<ul>
<li class="chapter" data-level="6.1" data-path="chapter6.html"><a href="chapter6.html#asbtract"><i class="fa fa-check"></i><b>6.1</b> Asbtract</a>
<ul>
<li class="chapter" data-level="6.1.1" data-path="chapter6.html"><a href="chapter6.html#objective"><i class="fa fa-check"></i><b>6.1.1</b> Objective</a></li>
<li class="chapter" data-level="6.1.2" data-path="chapter6.html"><a href="chapter6.html#methods"><i class="fa fa-check"></i><b>6.1.2</b> Methods</a></li>
<li class="chapter" data-level="6.1.3" data-path="chapter6.html"><a href="chapter6.html#results"><i class="fa fa-check"></i><b>6.1.3</b> Results</a></li>
<li class="chapter" data-level="6.1.4" data-path="chapter6.html"><a href="chapter6.html#conclusion-1"><i class="fa fa-check"></i><b>6.1.4</b> Conclusion</a></li>
<li class="chapter" data-level="6.1.5" data-path="chapter6.html"><a href="chapter6.html#keywords"><i class="fa fa-check"></i><b>6.1.5</b> Keywords</a></li>
</ul></li>
<li class="chapter" data-level="6.2" data-path="chapter6.html"><a href="chapter6.html#introduction"><i class="fa fa-check"></i><b>6.2</b> Introduction</a></li>
<li class="chapter" data-level="6.3" data-path="chapter6.html"><a href="chapter6.html#methods-1"><i class="fa fa-check"></i><b>6.3</b> Methods</a></li>
<li class="chapter" data-level="6.4" data-path="chapter6.html"><a href="chapter6.html#results-1"><i class="fa fa-check"></i><b>6.4</b> Results</a></li>
<li class="chapter" data-level="6.5" data-path="chapter6.html"><a href="chapter6.html#discussion"><i class="fa fa-check"></i><b>6.5</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="chapter7.html"><a href="chapter7.html"><i class="fa fa-check"></i><b>7</b> Clustering metabolites</a></li>
<li class="chapter" data-level="8" data-path="chapter8.html"><a href="chapter8.html"><i class="fa fa-check"></i><b>8</b> Rules for instrumenting clusters</a></li>
<li class="chapter" data-level="9" data-path="chapter9.html"><a href="chapter9.html"><i class="fa fa-check"></i><b>9</b> Mendelian randomization analysis: stage 2</a></li>
<li class="chapter" data-level="" data-path="conclusion-2.html"><a href="conclusion-2.html"><i class="fa fa-check"></i>Conclusion</a></li>
<li class="chapter" data-level="" data-path="appendix-appendix.html"><a href="appendix-appendix.html"><i class="fa fa-check"></i>(APPENDIX) Appendix</a></li>
<li class="chapter" data-level="10" data-path="section.html"><a href="section.html"><i class="fa fa-check"></i><b>10</b> </a></li>
<li class="chapter" data-level="11" data-path="section-1.html"><a href="section-1.html"><i class="fa fa-check"></i><b>11</b> </a>
<ul>
<li class="chapter" data-level="11.1" data-path="section-1.html"><a href="section-1.html#code-from-chapter-refchapter1"><i class="fa fa-check"></i><b>11.1</b> Code from Chapter @ref(chapter1)</a></li>
<li class="chapter" data-level="11.2" data-path="section-1.html"><a href="section-1.html#code-from-chapter-refchapter2"><i class="fa fa-check"></i><b>11.2</b> Code from Chapter @ref(chapter2)</a></li>
<li class="chapter" data-level="11.3" data-path="section-1.html"><a href="section-1.html#code-from-chapter-refchapter3"><i class="fa fa-check"></i><b>11.3</b> Code from Chapter @ref(chapter3)</a></li>
<li class="chapter" data-level="11.4" data-path="section-1.html"><a href="section-1.html#code-from-chapter-refchapter4"><i class="fa fa-check"></i><b>11.4</b> Code from Chapter @ref(chapter4)</a></li>
<li class="chapter" data-level="11.5" data-path="section-1.html"><a href="section-1.html#code-from-chapter-refchapter5"><i class="fa fa-check"></i><b>11.5</b> Code from Chapter @ref(chapter5)</a></li>
<li class="chapter" data-level="11.6" data-path="section-1.html"><a href="section-1.html#code-from-chapter-refchapter6"><i class="fa fa-check"></i><b>11.6</b> Code from Chapter @ref(chapter6)</a></li>
<li class="chapter" data-level="11.7" data-path="section-1.html"><a href="section-1.html#code-from-chapter-refchapter7"><i class="fa fa-check"></i><b>11.7</b> Code from Chapter @ref(chapter7)</a></li>
<li class="chapter" data-level="11.8" data-path="section-1.html"><a href="section-1.html#code-from-chapter-refchapter8"><i class="fa fa-check"></i><b>11.8</b> Code from Chapter @ref(chapter8)</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./"></a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="chapter1" class="section level1">
<h1 number="1"><span class="header-section-number">1</span> Introduction</h1>
<style>
body {
text-align: justify}
</style>
<div id="increased-adiposity-and-associtions-with-disease" class="section level2">
<h2 class="unnumbered" number=""><em>Increased adiposity and associtions with disease</em></h2>
<p>This chapter provides background for the association between overweight and obesity and disease and sets out the aims and objectives of this thesis. It explores the components and functions of adipose tissue, how we traditionaly measure increased adiposity, additional measures and their associations with disease, where we lack biological understanding of associations with disease and how we might expand our knowledge of this area.</p>
</div>
<div id="background" class="section level2">
<h2 number="1.1"><span class="header-section-number">1.1</span> Background</h2>
<p>The number of individuals suffering from overweight and obesity is at an all time high. Globally, 39% and 13% of adults (18+) are estimated to be overweight or obese<span class="citation"><sup><a href="#ref-WorldHealthOrganisation2018" role="doc-biblioref">1</a></sup></span>(Figure <a href="chapter1.html#fig:overweight-graph">1</a> and <a href="chapter1.html#fig:obesity-graph">2</a>) and this number is expected to continue to rise<span class="citation"><sup><a href="#ref-Ng2014" role="doc-biblioref">2</a>–<a href="#ref-Abarca-Gomez2017" role="doc-biblioref">4</a></sup></span>. It is estimated that obesity is repsonsible for 8% of global deaths<span class="citation"><sup><a href="#ref-Stanaway2018" role="doc-biblioref">5</a></sup></span>(Figure <a href="chapter1.html#fig:mortality-graph">3</a>). With the number of overweight and obese individuals increasing<span class="citation"><sup><a href="#ref-Ng2014" role="doc-biblioref">2</a>–<a href="#ref-Abarca-Gomez2017" role="doc-biblioref">4</a></sup></span> it is likely the number of premature deaths will rise too. <br></p>
<p>Conventionally, overweight and obesity is measured using body mass index (BMI), with overweight and obesity classified as a BMI of 25–29.9 kg/m<sup>2</sup> and &gt; 30 kg/m<sup>2</sup> respectively. A normal weight classification is a BMI of 18.5–24.9 kg/m<sup>2</sup>, with an underweight class below this. In the crudest sense, BMI is a measure of weight given an adjustment of height. Given this simplicity and the association with a range of health outcomes (see section <a href="chapter1.html#BMI-disease"><strong>??</strong></a>), it is seen as a sensible measure of increased adiposity and therefore risk. Underweight is a specific condition that may be secondary to or symptomatic of an underlying disease and is not within the scope of this thesis. <br></p>
<div class="figure" style="text-align: center"><span id="fig:overweight-graph"></span>
<img src="data/chapter1/share-of-adults-who-are-overweight.png" alt="Proportion of overweight individuals" width="100%" />
<p class="caption">
Figure 1: Proportion of overweight individuals
</p>
</div>
<p>
<em>Figure <a href="chapter1.html#fig:overweight-graph">1</a>, reproduced from Ritchie and Roser (2019)<span class="citation"><sup><a href="#ref-Ritchie2019" role="doc-biblioref">6</a></sup></span>, shows the share of adults (18+) that are overweight globally and in 5 selected geographic regions (Americas, Europe, Eastern Mediteranean, Africa and Sout East Asia) from 1975 to 2016.</em> <br></p>
<div class="figure" style="text-align: center"><span id="fig:obesity-graph"></span>
<img src="data/chapter1/share-of-adults-defined-as-obese.png" alt="Proportion of obese individuals" width="100%" />
<p class="caption">
Figure 2: Proportion of obese individuals
</p>
</div>
<p>
<em>Figure <a href="chapter1.html#fig:obesity-graph">2</a>, reproduced from Ritchie and Roser (2019)<span class="citation"><sup><a href="#ref-Ritchie2019" role="doc-biblioref">6</a></sup></span>, shows the share of adults (18+) that are obese globally and in 5 selected geographic regions (Americas, Europe, Eastern Mediteranean, Africa and Sout East Asia) from 1975 to 2016.</em> <br></p>
<div class="figure" style="text-align: center"><span id="fig:mortality-graph"></span>
<img src="data/chapter1/number-of-deaths-by-risk-factor.png" alt="Number of deaths by risk factor" width="100%" />
<p class="caption">
Figure 3: Number of deaths by risk factor
</p>
</div>
<p>
<em>Figure <a href="chapter1.html#fig:mortality-graph">3</a>, reproduced from Ritchie and Roser (2019)<span class="citation"><sup><a href="#ref-Ritchie2019" role="doc-biblioref">6</a></sup></span>, shows the number of deaths for 26 risk factors globally in 2017 for all age groups. Obesity is the 5th leading cause of death with 3.41 million deaths in 2017.</em> <br></p>
</div>
<div id="adipose-tissue" class="section level2">
<h2 number="1.2"><span class="header-section-number">1.2</span> Adipose tissue</h2>
<p>Ones weight is made up of two components, fat mass and fat free mass, of which fat free mass encompasses muscle, bone and water mass. Fat mass is an all encompassing term for adipose tissue. Adipose tissue is predominantly made up of adipocytes, with other tissues and cells such as the stromal vascular fraction, preadipocytes and fibroblasts making up smaller proprotions<span class="citation"><sup><a href="#ref-Frayn2003" role="doc-biblioref">7</a>–<a href="#ref-Luo2016" role="doc-biblioref">9</a></sup></span>. The main function of adipose tissue is energy storage in the form of lipids, with a secodnary function to insulate and chushion the body. These two functions can broadly be seperated into two types of adipose tissue, white and brown<span class="citation"><sup><a href="#ref-Cohen2016" role="doc-biblioref">8</a></sup></span>. In addition to these functions adipose tissues is considered an endocrine organ, responsive to afferent signalling as well as being a prolific signaller its self<span class="citation"><sup><a href="#ref-Kershaw2004" role="doc-biblioref">10</a></sup></span>. Advances in genetics and availability of large population studies has also enabled the identification of single nucleotide polymorphisms (SNPs) and genes associated with adipose tissue<span class="citation"><sup><a href="#ref-Dahlman2010" role="doc-biblioref">11</a></sup></span>. All of these factors, including the composition of adipose tissue, can be affected by obesity and in turn contribute to the development of obesity and progression to disease. <br></p>
<div id="energy-fat-storage" class="section level3">
<h3 number="1.2.1"><span class="header-section-number">1.2.1</span> Energy (fat) storage</h3>
<p>Energy storage is a balancing act dertemined by energy intake and energy expenditure, where an increase or decrease in one leads to a change in total energy storage. The make up of ones energy stores is comprosied primarily of proteins, carbohydrates, and fats. For protein, there is little change in total energy stores outside of a growth stimulus (i.e. exercise is needed to increase protein stores)<span class="citation"><sup><a href="#ref-Galgani2008" role="doc-biblioref">12</a></sup></span>. Carbohydrate stores fluctuate markedly throughout the day as a result of limited storage and their comrpising the majority of energy production<span class="citation"><sup><a href="#ref-Galgani2008" role="doc-biblioref">12</a></sup></span>. The largest energy store is fats and much like proteins, daily intake is ~1% of their total store<span class="citation"><sup><a href="#ref-Galgani2008" role="doc-biblioref">12</a></sup></span>. Because of tight controls over protein and limited availability of carbohydrate storage, fat storage is the only expandable resevoir of excess energy intake[<span class="citation"><a href="#ref-Frayn2003" role="doc-biblioref">7</a></span>; Galgani2008]. As a result, an energy imbalance will be reflected in the fat stores and not elsewhere<span class="citation"><sup><a href="#ref-Frayn2003" role="doc-biblioref">7</a>,<a href="#ref-Galgani2008" role="doc-biblioref">12</a></sup></span>. <br></p>
<p>Excess energy is stored in adipocytes in the form of lipid droplets (triglycerides; Figure <a href="chapter1.html#fig:adipocyte">4</a>) via lipogensis. The release of these fat stores, in the form of fatty acids, occurs through lipolysis. As the only store of excess energy, triglycerides provide an accurate reflection of energy imbalance, while adipocytes reflect the deposition and mobilisation of triglycerides<span class="citation"><sup><a href="#ref-Frayn2003" role="doc-biblioref">7</a></sup></span>. Deposition and mobilisation of triglycerides, depicted in Figure <a href="chapter1.html#fig:adipocyte">4</a>, is a product of a complex interplay of genetic and hormonal signals with leptin and insulin playing key roles<span class="citation"><sup><a href="#ref-Amitani2013" role="doc-biblioref">13</a></sup></span>. Insulin stimulates the conversion of acetyl-CoA to triglycerides by encouraging uptake of glucose by adipocytes and promoting expression of SREBP1 (sterol regulatory element-binding protein 1). SREBP1 regulates fatty acid, triglyceride and cholesterol synthesis<span class="citation"><sup><a href="#ref-Frayn2003" role="doc-biblioref">7</a>,<a href="#ref-Luo2016" role="doc-biblioref">9</a></sup></span>. In addition, lipoprotein lipase plays a key role in hydrolysing circulating triglycerides into fatty acids enabling their uptake by adipocytes<span class="citation"><sup><a href="#ref-Frayn2003" role="doc-biblioref">7</a></sup></span>. Adipocytes however have limited storage capacity for triglycerides, and though they can expand, they also have the the ability multiply once capacity is reacherd<span class="citation"><sup><a href="#ref-Frayn2003" role="doc-biblioref">7</a></sup></span>. The amount of expansion adipocytes can achieve is limited<span class="citation"><sup><a href="#ref-Frayn2003" role="doc-biblioref">7</a>,<a href="#ref-Gray2007" role="doc-biblioref">14</a></sup></span> and thought to be influential in the rate of adipogenesis, mobilisation of fats around the body and development of disease<span class="citation"><sup><a href="#ref-Gray2007" role="doc-biblioref">14</a></sup></span>.<br></p>
<div class="figure" style="text-align: center"><span id="fig:adipocyte"></span>
<img src="data/chapter1/adipocyte.png" alt="Diagram of adipocyte fat deposition and mobilisation" width="100%" />
<p class="caption">
Figure 4: Diagram of adipocyte fat deposition and mobilisation
</p>
</div>
<p>
<em>Figure <a href="chapter1.html#fig:adipocyte">4</a>, reproduced from Frayn et al. (2003)<span class="citation"><sup><a href="#ref-Frayn2003" role="doc-biblioref">7</a></sup></span>, depicts influences on adipocytes that result in fat storage. Stimuli such as insulin result in positive (+) fat deposition, while other stimuli such as cortisol may result in positive or negative (-) fat deposition depedning on the location of the adipocyte within the body. ANP, atrial natriuretic peptide, FA, fatty acids; LPL, lipoprotein lipase; TG, triglyceride; TRL, TG-rich lipoproteins.</em> <br></p>
</div>
<div id="insulation-and-cushioning" class="section level3">
<h3 number="1.2.2"><span class="header-section-number">1.2.2</span> Insulation and cushioning</h3>
<p>Energy storage of fats is managed predominantly by white adipose tissue. These deposits are located mainly within subcutaneous tissue. During infancy brown adipose tissue is abundant, however as humans age these deposits <em>‘whiten’</em> leaving few adult brown fat deposits. These adult deposits are located around the neck, thoracic section of the spine, aortic body, and adrenal glands; all locations with high blood flow<span class="citation"><sup><a href="#ref-Luo2016" role="doc-biblioref">9</a>,<a href="#ref-Cannon2004" role="doc-biblioref">15</a></sup></span>. Thermogenesis by these tissues is regulated by the hypothalamus and is achieved by uncoupling of the respiratory chain of oxidative phosphorylation via UCP1(uncoupling protein 1). When active, lipids and glucose are used as fuel<span class="citation"><sup><a href="#ref-Cannon2004" role="doc-biblioref">15</a></sup></span> Due to the abundant vascularization of areas where brown adipose tissue is located the heat generated from this process is quickly distributed via the circulatory system. In addition, white adipose tissue can undergo a <em>‘beiging’</em> process taking on thermogenic properties of brown adipose tissue. Beige adipsoe tissue is a half way point between white and brown adipose tissue and is more widely dispersed than brown adipose tissue being located mainly within subcutaneous white adipose tissue. It is cold activated but can be recruited through signalling that mimics the stressed state induced by cold. The <em>‘beiging’</em> process is not well characterized but is thought to be a result of signalling changes during differentiation of preadipocytes<span class="citation"><sup><a href="#ref-Luo2016" role="doc-biblioref">9</a></sup></span>. Though the <em>‘beiging’</em> process is reversible it has been suggested as a therapeutic for weight loss.<span class="citation"><sup><a href="#ref-Cannon2004" role="doc-biblioref">15</a></sup></span> <br></p>
</div>
<div id="signalling" class="section level3">
<h3 number="1.2.3"><span class="header-section-number">1.2.3</span> Signalling</h3>
<p>It is important to consider adipose tissue as not solely adipocytes but rather an organ in its own right, comprised of a multitude of tissues and cells including connective and nerve tissues and immune cells. All respond to and secrete signalling molecules locally and systemically. It is thought this signalling is primarily to maintain appropriate energy stores and includes signals influincing deposition and mobilisation of fats and differntiation of new adipocytes<span class="citation"><sup><a href="#ref-Frayn2003" role="doc-biblioref">7</a>,<a href="#ref-Luo2016" role="doc-biblioref">9</a>,<a href="#ref-Kershaw2004" role="doc-biblioref">10</a></sup></span>. Functionally, signalling molecules have metabolic effects and/or are involved in steroid hormone production<span class="citation"><sup><a href="#ref-Kershaw2004" role="doc-biblioref">10</a></sup></span>. <br></p>
<p>First, adipogenesis must occur. Adipogenesis has been well characterized and PPAR<span class="math inline">\(y\)</span> (peroxisome proliferator-activated receptor <span class="math inline">\(y\)</span>) is the master regulator<span class="citation"><sup><a href="#ref-Frayn2003" role="doc-biblioref">7</a>,<a href="#ref-Luo2016" role="doc-biblioref">9</a></sup></span>, with overexpression leading to differntiation and underexpression resulting in lipodystrophy. Other signalling molecules such as KLFs (Kruppel-like factors) and C/EBPs influence adipogeneises through PPAR<span class="math inline">\(y\)</span><span class="citation"><sup><a href="#ref-Luo2016" role="doc-biblioref">9</a></sup></span>. Because of the master regulatory function of PPAR<span class="math inline">\(y\)</span> in adipogenesis, exploring regulatory function and expression has been considered as a potential avenue for therapeutics for obesity<span class="citation"><sup><a href="#ref-Luo2016" role="doc-biblioref">9</a>,<a href="#ref-Lee2014" role="doc-biblioref">16</a></sup></span>. Though not well characterized, brown adipocytes are thought be influenced heavily by PRDM16 and PGC1<span class="math inline">\(a\)</span>, with the latter required for thermogenesis and not necessarily adipogenesis<span class="citation"><sup><a href="#ref-Luo2016" role="doc-biblioref">9</a></sup></span>. The breakdown of stored triglycerides via lipolysis results in release of fatty acids and glycerol molecules for oxidation and gluconeogenesis respectively. Fatty acids can also be broken down into ketone bodies via ketogenesis. While insulin abundance activates lipogenesis, relative absence of insulin promotes lipogenesis. The lipolytic pathway, which is also activated by cAMP-dependent PKA (protein kinase A), relies on the function of ATGL (adipocyte triglyceride lipase) and HSL (hormone sensitive lipase) to catalyze the hydrolysis of triglycerides to di- and monoglycerides respectively. Inhibition of ATGL can result in imparied lipolysis and obesity<span class="citation"><sup><a href="#ref-Schreiber2019" role="doc-biblioref">17</a></sup></span>. <br></p>
<p>The signalling molecules adipocytes produce, known as adipokines, are numerous and act on the auto- and endocrine systems<span class="citation"><sup><a href="#ref-Lehr2012" role="doc-biblioref">18</a>,<a href="#ref-Fasshauer2015" role="doc-biblioref">19</a></sup></span>. There are both deposit specific effects on expression and secretion of adipokines and the movement these adipokines can be expected to undertake; subcutaneous adipose tissue adipokines travel through the systemic system while visceral adipose tissue adipokines can travel via the portal system with direct access to the liver. Adipocyte receptors are also expressed differentially based on deposit location<span class="citation"><sup><a href="#ref-Kershaw2004" role="doc-biblioref">10</a></sup></span>. The main adipokines (Figure <a href="chapter1.html#fig:adipokines">5</a>) produced by adipocytes include leptin and adiponectin, function to regulate metabolism and inflammation systemically. Other cells within the adipose tissue, including immune and endothelial cells, produce much of the other adipokines such as TNF<span class="math inline">\(a\)</span> (tumour necrosis factor <span class="math inline">\(a\)</span>) and IL6 (interleukin 6)<span class="citation"><sup><a href="#ref-Luo2016" role="doc-biblioref">9</a></sup></span>. Abnormal levels of adipokines is harmful, leading to impaired adipose tissue function and subsequent downstream effects such as insulin resistance<span class="citation"><sup><a href="#ref-Luo2016" role="doc-biblioref">9</a>,<a href="#ref-Fasshauer2015" role="doc-biblioref">19</a>–<a href="#ref-Bluher2015" role="doc-biblioref">21</a></sup></span>. The likelihood of abnormal levels is raised with increases in adipose tissue. This is of particular interest as adipokine levels can change as a result of diseases such as obesity, thus introducing feed-back loops which serve to alter normal processes<span class="citation"><sup><a href="#ref-Fasshauer2015" role="doc-biblioref">19</a>,<a href="#ref-Bluher2013" role="doc-biblioref">20</a></sup></span>. As such, adipokines offer potential therapeutic routes for diseases such as obesity. However, there are outstanding questions about how abnormal levels of adipokines leads to development of disease<span class="citation"><sup><a href="#ref-Fasshauer2015" role="doc-biblioref">19</a></sup></span>. For detailed discussion of adipokines and the pathways that lead to their production see<span class="citation"><sup><a href="#ref-Luo2016" role="doc-biblioref">9</a>,<a href="#ref-Kershaw2004" role="doc-biblioref">10</a>,<a href="#ref-Fasshauer2015" role="doc-biblioref">19</a>–<a href="#ref-Bluher2015" role="doc-biblioref">21</a></sup></span>.<br></p>
<div class="figure" style="text-align: center"><span id="fig:adipokines"></span>
<img src="data/chapter1/adipokines.jpeg" alt="Diagram of the main adipokines secreted by adipose tiusse" width="100%" />
<p class="caption">
Figure 5: Diagram of the main adipokines secreted by adipose tiusse
</p>
</div>
<p>
<em>Figure <a href="chapter1.html#fig:adipokines">5</a>, reproduced from Luo and Liu (2016)<span class="citation"><sup><a href="#ref-Luo2016" role="doc-biblioref">9</a></sup></span>, shows the main adipokines secreted by adipose tissue and their local and systemic functions. ASP, acylating simulation protein; FGF21, fibroblast growth factor 21; IL6, interleukin 6; MCP1, monocyte chemoattractant protein 1; PAI1, plasminogen activator inhibitor 1; TNF<span class="math inline">\(a\)</span>, tumour necrosis factor alpha.</em> <br></p>
</div>
<div id="genetics" class="section level3">
<h3 number="1.2.4"><span class="header-section-number">1.2.4</span> Genetics</h3>
<p>Production of adipokines, though partly a response of affernet signalling, is also a result of adipocyte genetics. This is also the case for lipogenesis, storage capacity, lipolysis and mobilisation and energy expenditure<span class="citation"><sup><a href="#ref-Dahlman2010" role="doc-biblioref">11</a></sup></span>. A number of adipose specific genes have been identified including <em>LEP</em><span class="citation"><sup><a href="#ref-Pan2018" role="doc-biblioref">22</a>,<a href="#ref-Ahn2019" role="doc-biblioref">23</a></sup></span>, <em>ADIPOQ</em><span class="citation"><sup><a href="#ref-Achari2017" role="doc-biblioref">24</a></sup></span>, and <em>PPAR<span class="math inline">\(y\)</span></em><span class="citation"><sup><a href="#ref-Ahn2019" role="doc-biblioref">23</a>,<a href="#ref-Lefterova2009" role="doc-biblioref">25</a></sup></span> encoding the adipokines leptin and adiponectin and the adipose-specific transcription factor PPAR<span class="math inline">\(y\)</span> respectively. These identified genes, and others<span class="citation"><sup><a href="#ref-Ahn2019" role="doc-biblioref">23</a></sup></span>, also show differential gene expression within adipose tissue compared with non-adipose tissue. Interestingly differential gene expression is also apparent between these genese in subcutaneous and visceral adipose tissue<span class="citation"><sup><a href="#ref-Ahn2019" role="doc-biblioref">23</a></sup></span>. The differential gene expression among adipose tissues would align with the different functions associated with subcutaneous and visceral adipose tissue. Differential expression along with the presence of adipose-specific genes is associated with obesity and related diseases<span class="citation"><sup><a href="#ref-Ahn2019" role="doc-biblioref">23</a></sup></span>, for example <em>SLC19A3</em> is an adipose-specific gene<span class="citation"><sup><a href="#ref-Ahn2019" role="doc-biblioref">23</a></sup></span> encoding a thiamine transporter and thiamine dependent enzymes have been associated with obesity[Maguire2018]. As adipocyte expandability is limited, and given that an excess of fatty acids results in increased adipogenesis<span class="citation"><sup><a href="#ref-Frayn2003" role="doc-biblioref">7</a>,<a href="#ref-Gray2007" role="doc-biblioref">14</a></sup></span> it is possible that expandability and thus the point at which mobilization of fatty acids to alternative depots occurs is fixed by adipose-specifc genes and expression. This may have an impact on development of diseases such as type-2 diabetes where incidence is markedly different in populations of different ancestries whom have the same BMI<span class="citation"><sup><a href="#ref-Ma2013a" role="doc-biblioref">26</a></sup></span>.</p>
</div>
</div>
<div id="BMI-disease" class="section level2">
<h2 number="1.3"><span class="header-section-number">1.3</span> BMI and disease</h2>
<p>With obesity responsible for 8% of premature deaths per-year<span class="citation"><sup><a href="#ref-Stanaway2018" role="doc-biblioref">5</a></sup></span> and more people expected to be overweight or obese in the coming years<span class="citation"><sup><a href="#ref-Ng2014" role="doc-biblioref">2</a>–<a href="#ref-Abarca-Gomez2017" role="doc-biblioref">4</a></sup></span> it is important to understand the reasons leading to mortality. In order to gain a better understanding of the relationship between BMI and mortality we used MELODI<span class="citation"><sup><a href="#ref-Elsworth2018" role="doc-biblioref">27</a></sup></span>, a literature mining tool, to identify intermediates in the direction of BMI towards mortality. MELODI creates individual article sets based on search terms, in this case an article set for ‘body mass index’ and an article set for ‘mortality’, and looks for enriched overlapping terms. MELODI uses PubMed, a data base of health and biomedical research literature with &gt; 30million items, and SemMedDB, a semantic predications repository built from PubMed citations, to identify enriched terms. Enrichment is a two-step process that firstly identifies overlapping terms in the article sets, and secondly quantifies the degree of overlap given the observed and expected frequency of terms across all articles not just those included in the article stes. Enrichment aims to reduce the amount of noise introduced when searching hundreds of thousands of articles, however manual curation is likely to be needed in order to obtain an informative list of intermediates. Manual curation will introduce bias. Publication bias will influence the use of literature mining tools, however, manual curation is likely to introduce more bias and is unfeasible at such a large scale as that achieved by literature mining tools. <br></p>
<p>We used MELODI to search for all articles published from 01/01/2000–09/12/2019 (maximum number of articles per article set is 1,000,000). Full results are available - <a href="https://github.com/mattlee821/000_thesis/index/data/chapter1">github.com/mattlee821/000_thesis/index/data/chapter1</a>. A total of 187951 and 787451 articles were retrieved and included in the article sets for ‘body mass index’ and ‘mortality’ respectively. Using the SemMedDB Triple results a total of 10828 enriched overlapping terms were identified. This included similar terms to ‘body mass index’ as the source. We first filtered for only ‘body mass index’ (n = 424). A Bonferroni corrected p-value (1.2^{-4}) removed 0 results. We then filtered for unqiue terms (n = 156) and removed the following categories which may have been included because of noise: Age Group (n = 152), Bacterium (included because of confounding with pneumonia; n = 4), finding (not an official MELODI category; n = 1), general (not an official MELODI category; n = 1), Fungus (included because of confounding with pneumonia; n = 2), Health Care Activity (n = 5), Human (n = 14), Injury or Poisoning (n = 1), Mammal (animal studies; n = 1), Patient or Disabled Group (n = 8), Population Group (n = 14), Sign or Symptom (n = 1), Virus (included because of confounding; n = 3).</p>
<p>We manually removed the following terms and merged them into the included term immunocompromised host: infections, hospital and opportunistic infections. We manually removed the following terms because of duplication under different names: cardiac death, sudden death, and sudden cardiac death (merged into cessation of life); coronary arteriosclerosis (atherosclerosis); cardiovascular morbidity, cardiac event, heart diseases, vascular diseases (cardiovascular diseases); depressed mood (depressive disorder); diabetes mellitus and diabetes mellitus, insulin-dependent (diabetic); metabolic diseases (metabolic syndrome). We manually removed the following terms because they were top-level categories that could either include a wide variety of terms already included or were duplicated by other terms: chronic disease, critical illness, disability, pregnancy complications and perinatal morbidity (pregnancy), pathogenesis. As a result of filtering we were left with 77 terms. We combined these terms into 9 categories including an ‘other’ category for traits that did not fit into one of any of the other categories (Table <a href="chapter1.html#tab:MELODI-final-table">1</a>). <br></p>
<table class="table" style="width: auto !important; margin-left: auto; margin-right: auto;">
<caption>
<span id="tab:MELODI-final-table">Table 1: </span>Intermediates identified between BMI and all targets using MELODI
</caption>
<thead>
<tr>
<th style="text-align:left;">
Cancer
</th>
<th style="text-align:left;">
Cardiovascular
</th>
<th style="text-align:left;">
Immune
</th>
<th style="text-align:left;">
Kidney
</th>
<th style="text-align:left;">
Liver
</th>
<th style="text-align:left;">
Neurological.behavioural
</th>
<th style="text-align:left;">
Pregnancy
</th>
<th style="text-align:left;">
Respiratory
</th>
<th style="text-align:left;">
Other
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Primary carcinoma of the liver cells
</td>
<td style="text-align:left;">
Heart failure
</td>
<td style="text-align:left;">
Pancreatitis
</td>
<td style="text-align:left;">
End stage renal failure
</td>
<td style="text-align:left;">
Liver diseases
</td>
<td style="text-align:left;">
Depressive disorder
</td>
<td style="text-align:left;">
Pre-Eclampsia
</td>
<td style="text-align:left;">
Tuberculosis
</td>
<td style="text-align:left;">
Metabolic syndrome
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant neoplasm of stomach
</td>
<td style="text-align:left;">
Anemia
</td>
<td style="text-align:left;">
Inflammatory disorder
</td>
<td style="text-align:left;">
Kidney Failure, Chronic
</td>
<td style="text-align:left;">
Non-alcoholic fatty liver
</td>
<td style="text-align:left;">
Dementia
</td>
<td style="text-align:left;">
Pregnancy
</td>
<td style="text-align:left;">
Sleep Apnea, Obstructive
</td>
<td style="text-align:left;">
Cessation of life
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant neoplasm of prostate
</td>
<td style="text-align:left;">
Dyslipidemias
</td>
<td style="text-align:left;">
Immunocompromised Host
</td>
<td style="text-align:left;">
Glomerular Filtration Rate
</td>
<td style="text-align:left;">
Liver and Intrahepatic Biliary Tract Carcinoma
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Hypertension induced by pregnancy
</td>
<td style="text-align:left;">
Pneumonia
</td>
<td style="text-align:left;">
Malnutrition
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant neoplasm of lung
</td>
<td style="text-align:left;">
Cerebrovascular accident
</td>
<td style="text-align:left;">
Bacteremia
</td>
<td style="text-align:left;">
Kidney Diseases
</td>
<td style="text-align:left;">
Chronic liver disease
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Chronic Obstructive Airway Disease
</td>
<td style="text-align:left;">
Diabetic
</td>
</tr>
<tr>
<td style="text-align:left;">
Common Neoplasm
</td>
<td style="text-align:left;">
Cardiovascular Diseases
</td>
<td style="text-align:left;">
Septicemia
</td>
<td style="text-align:left;">
Kidney Failure
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Respiration Disorders
</td>
<td style="text-align:left;">
Multiple Organ Failure
</td>
</tr>
<tr>
<td style="text-align:left;">
Liver neoplasms
</td>
<td style="text-align:left;">
Atherosclerosis
</td>
<td style="text-align:left;">
Lupus Erythematosus, Systemic
</td>
<td style="text-align:left;">
Renal function
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Respiratory Distress Syndrome, Adult
</td>
<td style="text-align:left;">
Fibrosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant disease
</td>
<td style="text-align:left;">
Myocardial Infarction
</td>
<td style="text-align:left;">
Sepsis Syndrome
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Respiratory Tract Infections
</td>
<td style="text-align:left;">
Deglutition Disorders
</td>
</tr>
<tr>
<td style="text-align:left;">
Carcinoma of the Large Intestine
</td>
<td style="text-align:left;">
Ischemic stroke
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Respiratory Failure
</td>
<td style="text-align:left;">
Vitamin D Deficiency
</td>
</tr>
<tr>
<td style="text-align:left;">
Pancreatic carcinoma
</td>
<td style="text-align:left;">
Acute coronary syndrome
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Acute respiratory failure
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Atrial Fibrillation
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Coronary heart disease
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Systemic arterial pressure
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Thrombosis
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Cerebrovascular Disorders
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Acute myocardial infarction
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Sinus rhythm
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Cardiomyopathies
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Myocardial Ischemia
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Peripheral Vascular Diseases
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Vascular calcification
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Heart Arrest
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Myocardial rupture
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Shock, Cardiogenic
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Hemorrhage
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Ischemia
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Congestive heart failure
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Ventricular Dysfunction, Left
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Mitral Valve Insufficiency
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
Hyperglycaemia
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;">
</td>
</tr>
</tbody>
</table>
<p>The majority of intermediates were cardiovascular related, we included any terms such as hyperglycaemia and dyslipidemia as both conditions are focussed on the blood. Few terms referenced specific pregnancy conditions and we merged a number of pregnancy terms (such as pregnancy complications) together. Our results (Table <a href="chapter1.html#tab:MELODI-final-table">1</a>) identified a number of intermediate categories and terms which may represent additional diseases not picked up through the enrichment process. In order to get a better understanidng of the traits within each of these categories that may be related to BMI we searched PubMed using ‘body mass index’ and 8 categories; we searched each of the terms in the other category individually. This search is summarised in <a href="chapter1.html#tab:literature-associations">2</a>. <br></p>
<table class="table" style="margin-left: auto; margin-right: auto;">
<caption>
<span id="tab:literature-associations">Table 2: </span>Associations identified in the literature
</caption>
<thead>
<tr>
<th style="text-align:left;">
Trait
</th>
<th style="text-align:left;">
Summary
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;width: 5em; ">
Cancer
</td>
<td style="text-align:left;width: 20em; ">
BMI is associated with many different cancers with differing hypothesis for biological pathways (e.g. metabolic, inflammatory, hormonal)<span class="citation"><sup><a href="#ref-Collaboration2009" role="doc-biblioref">41</a>,<a href="#ref-Bray2004" role="doc-biblioref">59</a>–<a href="#ref-Bhaskaran2014" role="doc-biblioref">61</a></sup></span>
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Cardiovascular
</td>
<td style="text-align:left;width: 20em; ">
Cardiovascular disease<span class="citation"><sup><a href="#ref-Khan2018" role="doc-biblioref">37</a>,<a href="#ref-Collaboration2009" role="doc-biblioref">41</a></sup></span>. Hypertension may be related to changes in: sympathetic activity, blood flow and viscosity, and dietary intake<span class="citation"><sup><a href="#ref-Bray2004" role="doc-biblioref">59</a>,<a href="#ref-Haslam2005" role="doc-biblioref">60</a>,<a href="#ref-Jayedi2018" role="doc-biblioref">62</a></sup></span>. Dyslipidemia and the reduction in HDL may be important in development of heart disease and the location of fat deposition may be important but this might also be subsequent to dyslipidemia and reduction in HDL<span class="citation"><sup><a href="#ref-Collaboration2009" role="doc-biblioref">41</a>,<a href="#ref-Bray2004" role="doc-biblioref">59</a>,<a href="#ref-Haslam2005" role="doc-biblioref">60</a>,<a href="#ref-Dagfinn2016" role="doc-biblioref">63</a></sup></span>. Strokes might be a reuslt of other co-morbidities and potentially dieatary increased salt intake<span class="citation"><sup><a href="#ref-Collaboration2009" role="doc-biblioref">41</a>,<a href="#ref-Haslam2005" role="doc-biblioref">60</a></sup></span>
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Immune
</td>
<td style="text-align:left;width: 20em; ">
Osteoarthritis is likely a result of the physical burden of increased mass. But also potential result of changes to cartilage and bone metabolism<span class="citation"><sup><a href="#ref-Bray2004" role="doc-biblioref">59</a>,<a href="#ref-Haslam2005" role="doc-biblioref">60</a></sup></span>
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Kidney
</td>
<td style="text-align:left;width: 20em; ">
Kidney disease<span class="citation"><sup><a href="#ref-Collaboration2009" role="doc-biblioref">41</a>,<a href="#ref-Bray2004" role="doc-biblioref">59</a></sup></span>
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Liver
</td>
<td style="text-align:left;width: 20em; ">
BMI is associated with many liver complications termed non-alcoholic fatty liver disease, which includes: hepatomegaly, altered enzymes, steatosis, steatohepatitis, fibrohsis, cirrhosis; the mechanisms are unclear<span class="citation"><sup><a href="#ref-Collaboration2009" role="doc-biblioref">41</a>,<a href="#ref-Bray2004" role="doc-biblioref">59</a>,<a href="#ref-Haslam2005" role="doc-biblioref">60</a></sup></span>. Increased risk of gallstones likely a result of increased cholesterol<span class="citation"><sup><a href="#ref-Bray2004" role="doc-biblioref">59</a></sup></span>
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Neurological/ behavioural
</td>
<td style="text-align:left;width: 20em; ">
Quality of life is affected by a collection of factors, not least other diseases, but evidence shows that stigmatisation as a result of increased fat mass may be the cause<span class="citation"><sup><a href="#ref-Bray2004" role="doc-biblioref">59</a>,<a href="#ref-Haslam2005" role="doc-biblioref">60</a></sup></span>. Dementia<span class="citation"><sup><a href="#ref-Beydoun2008" role="doc-biblioref">64</a></sup></span>
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Pregnancy
</td>
<td style="text-align:left;width: 20em; ">
Multiple symptoms including irregular menstration and reduced fertility, but the reasons aren’t fully known<span class="citation"><sup><a href="#ref-Bray2004" role="doc-biblioref">59</a></sup></span>
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Respiratory
</td>
<td style="text-align:left;width: 20em; ">
Physical burden of increased fat mass reduces FEV1, FVC, lung and residual capacity, as well as expiratory reserve; may also be a role for weakend muscles and compliance of the thorax<span class="citation"><sup><a href="#ref-Haslam2005" role="doc-biblioref">60</a>,<a href="#ref-Poulain2006" role="doc-biblioref">65</a></sup></span>. Issues with sleep are likely a result of chronic pulmonary diseases and the distribution of increased fat mass to the neck<span class="citation"><sup><a href="#ref-Bray2004" role="doc-biblioref">59</a>,<a href="#ref-Haslam2005" role="doc-biblioref">60</a>,<a href="#ref-Poulain2006" role="doc-biblioref">65</a></sup></span>
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Metabolic syndrome
</td>
<td style="text-align:left;width: 20em; ">
Metabolic syndrome []
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Mortality
</td>
<td style="text-align:left;width: 20em; ">
Years of life lost may be as many as 13 for obese individuals, though ethnic differences are apparent<span class="citation"><sup><a href="#ref-Bray2004" role="doc-biblioref">59</a>,<a href="#ref-Haslam2005" role="doc-biblioref">60</a></sup></span>
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Malnutrition
</td>
<td style="text-align:left;width: 20em; ">
Malnutrition []
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Diabetes
</td>
<td style="text-align:left;width: 20em; ">
A clear process: increased fat mass, impaired glucose clearance, increased insulin resistnace, wider metabolic changes, diabetes<span class="citation"><sup><a href="#ref-Collaboration2009" role="doc-biblioref">41</a>,<a href="#ref-Bray2004" role="doc-biblioref">59</a>,<a href="#ref-Haslam2005" role="doc-biblioref">60</a></sup></span>
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Multiple organ failure
</td>
<td style="text-align:left;width: 20em; ">
Multiple organ failure []
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Fibrosis
</td>
<td style="text-align:left;width: 20em; ">
Fibrosis []
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Deglutition disorders
</td>
<td style="text-align:left;width: 20em; ">
Deglutition disorders []
</td>
</tr>
<tr>
<td style="text-align:left;width: 5em; ">
Vitamin D deficiency
</td>
<td style="text-align:left;width: 20em; ">
Vitamin D deficiency []
</td>
</tr>
</tbody>
</table>
<p><em>Table <a href="chapter1.html#tab:literature-associations">2</a> gives a sumamry of evidence for udnerlying aetiology of the association of BMI with intermediates and intermediate categories identified through a MELODI literature mining search.</em> <br>
</p>
</div>
<div id="additional-measures" class="section level2">
<h2 number="1.4"><span class="header-section-number">1.4</span> Additional measures</h2>
<p>There are numerous diseases associated with BMI (Table <a href="chapter1.html#tab:MELODI-final-table">1</a>) and our udnerstanding of the underlying aetiology of these associations is growing (Table <a href="chapter1.html#tab:literature-associations">2</a>). However, use of BMI as a measure of increased adiposity, and thus as a measure of associated risk, is problematic as BMI does not have the resolution to accurately measure an individual’s body composition<span class="citation"><sup><a href="#ref-Pischon2008" role="doc-biblioref">28</a>–<a href="#ref-Pasco2012" role="doc-biblioref">31</a></sup></span>. Controversy has surrounded associations of BMI and mortality<span class="citation"><sup><a href="#ref-Flegal2013" role="doc-biblioref">32</a>–<a href="#ref-Elagizi2018" role="doc-biblioref">34</a></sup></span>. Though these controversies may be a result of confounding and other biases<span class="citation"><sup><a href="#ref-Banack2013" role="doc-biblioref">35</a>–<a href="#ref-Khan2018" role="doc-biblioref">37</a></sup></span> evidence has pointed to a more important role for fat deposition<span class="citation"><sup><a href="#ref-Sahakyan2015" role="doc-biblioref">38</a>,<a href="#ref-Hamer2017" role="doc-biblioref">39</a></sup></span>. As such, complimnetary assesment of increased adiposity using a combination of body composition measures may provide additional information into the associations with disease<span class="citation"><sup><a href="#ref-WorldHealthOrganisation2008" role="doc-biblioref">40</a>,<a href="#ref-Collaboration2009" role="doc-biblioref">41</a></sup></span>. <br></p>
<p>Alongside BMI, numerous measures have been used to assess increased fat mass. Among the most frequently used are waist hip ratio (WHR) and body fat percent (BF%). Both measures are used clinically and for population-based research to provide more accurate and complimentary measures of an individuals body composition. Additionally, they have two advantages over BMI. Firstly, WHR provides an assessment of the deposition of fat around the body; deposition of fat at the waist is indicative of greater visceral fat<span class="citation"><sup><a href="#ref-WorldHealthOrganisation2008" role="doc-biblioref">40</a></sup></span>. Secondly, BF% by its nature of measuring fat mass directly rather than estimating it like BMI, provides a more accurate estimation of body composition<span class="citation"><sup><a href="#ref-WorldHealthOrganisation2000" role="doc-biblioref">42</a></sup></span>. However, although WHR is a simple measure like BMI, BF% can be measured in a multitude of different ways from estimations based on WHR and BMI to dual-emission X-ray absorptiometry (DXA) imaging. This means it can be both a crude (and easy to measure) and very accurate (and costly to measure) measure of total fat mass. <br></p>
<div id="whr" class="section level3">
<h3 number="1.4.1"><span class="header-section-number">1.4.1</span> WHR</h3>
<p>WHR is associated with increased morbidity<span class="citation"><sup><a href="#ref-Dobbelsteyn2001" role="doc-biblioref">43</a>–<a href="#ref-Rost2018" role="doc-biblioref">46</a></sup></span></p>
</div>
<div id="bf" class="section level3">
<h3 number="1.4.2"><span class="header-section-number">1.4.2</span> BF%</h3>
<p>BF% is associated with increased morbidity<span class="citation"><sup><a href="#ref-Lee2018" role="doc-biblioref">47</a>–<a href="#ref-Jo2018" role="doc-biblioref">49</a></sup></span></p>
</div>
</div>
<div id="why-does-more-fat-mean-more-disease" class="section level2">
<h2 number="1.5"><span class="header-section-number">1.5</span> Why does more fat mean more disease?!?!?!</h2>
<p>The underlying aeitology of the association between increased adiposity and different diseases is not well characteised. This is likely because of the complex underpinnings of both exposure and outcome; environment and genetic factors play a complex role in BMI<span class="citation"><sup><a href="#ref-Albuquerque2017" role="doc-biblioref">50</a>–<a href="#ref-Loos2018" role="doc-biblioref">52</a></sup></span> and it is likely this is the case for many of the diseases associated with it. It may also be the case that these investigations are not applicbale because of lack of data from population based studies. Recent availability of large, and deeply phenotyped population based studies may provide the data necessary to disentangle this complex question<span class="citation"><sup><a href="#ref-Sudlow2015" role="doc-biblioref">53</a></sup></span>. <br></p>
<div id="causal-analysis-set-up-sr-and-future-work" class="section level3">
<h3 number="1.5.1"><span class="header-section-number">1.5.1</span> Causal analysis (set up SR and future work)</h3>
<p>Mendelian randomization (MR), a statistical method that uses genetic variants associated with a trait as an instrumental variable. MR has been described<span class="citation"><sup><a href="#ref-DaveySmith2003" role="doc-biblioref">54</a>,<a href="#ref-Davies2018" role="doc-biblioref">55</a></sup></span> and reviewed elsewhere<span class="citation"><sup><a href="#ref-Burgess2015" role="doc-biblioref">56</a>,<a href="#ref-Bowden2019" role="doc-biblioref">57</a></sup></span> and a regularly updated dictionary is available <a href="https://doi.org/10.31219/osf.io/6yzs7">https://doi.org/10.31219/osf.io/6yzs7</a>.</p>
</div>
</div>
<div id="metabolites-are-gr8" class="section level2">
<h2 number="1.6"><span class="header-section-number">1.6</span> metabolites are gr8</h2>
</div>
<div id="aims" class="section level2">
<h2 number="1.7"><span class="header-section-number">1.7</span> Aims</h2>
<p>Overweight and obesity is a global health concern with hundreds of millions of individuals affected and many millions dying each year<span class="citation"><sup><a href="#ref-WorldHealthOrganisation2018" role="doc-biblioref">1</a>–<a href="#ref-Stanaway2018" role="doc-biblioref">5</a></sup></span>. The consequences of overweight and obesity are driven by increased fat mass[@] leading to the development of numerous diseases[@]. The progression from increased adiposity to diseases development, the biological pathways involved, are unclear[@]. Adipose tissue is a prolific signalling organ resulting in systemic changes across the body[@]. Metabolic changes may be a result of increased adiposity and subsequent signalling[@] and evidence has highlited the role of metabolites in disease[@]. The aim of this thesis is to: <br></p>
<ul>
<li><strong>Identify metabolites that sit on the cuasal pathway from increased adiposity to disease</strong></li>
</ul>
</div>
<div id="objectives" class="section level2">
<h2 number="1.8"><span class="header-section-number">1.8</span> Objectives</h2>
<p>In order to achieve this aim and better understand the biological mechanisms underlying development of disease this thesis will:</p>
<ol style="list-style-type: decimal">
<li>Identify all traits causally associated with increased adiposity
<ul>
<li>we will perform a systematic review of allMenderlin randomization studies investigating measures of increased adiposity with any outcome</li>
<li>we will use the findings from this review to guide subsequent work <br></li>
</ul></li>
</ol>
<ol start="2" style="list-style-type: decimal">
<li>Identify and describe appropriate instrumentation of increased adiposity <br></li>
</ol>
<ol start="3" style="list-style-type: decimal">
<li>Identify metabolites associated with increased adiposity
<ul>
<li>We will use observational and Mendelian randomization analyses to identify metabolites associated with multiple measures of increased adiposity <br></li>
</ul></li>
</ol>
<ol start="4" style="list-style-type: decimal">
<li>Design and implement methods to cluster metabolites
<ul>
<li>Metabolites are complicated and highly correlated; we will develop methods to cluster metabolites and propose rules for instrumenting metabolites and clusters for Mendelian randomization analyses <br></li>
</ul></li>
</ol>
<ol start="5" style="list-style-type: decimal">
<li>Identify diseases associated with metabolites
<ul>
<li>We will use observational and Mendelian randomization analyses to identify metabolites associated with diseases</li>
<li>We will be guided by the systematci review and metabolites we identify as associated with increased adiposity <br></li>
</ul></li>
</ol>
</div>
<div id="notes-for-writing" class="section level2">
<h2 number="1.9"><span class="header-section-number">1.9</span> Notes for writing</h2>
</div>
<div id="conclusion" class="section level2">
<h2 number="1.10"><span class="header-section-number">1.10</span> Conclusion</h2>
<p>Evidence has suggested that fat mass or the relative proportions of fat mass and fat free mass, rather than fat free mass alone, are the aspects of BMI associated with all cause and cause specific mortality<span class="citation"><sup><a href="#ref-Lee2018" role="doc-biblioref">47</a></sup></span>(evidence may differ for women).</p>
<p>Fat free mass, or lean mass, has been shown toThough indoividual body composition is variable for a given BMI, at a population level BMI provides a broadly accurate readout of fat mass<span class="citation"><sup><a href="#ref-Pouliot1994" role="doc-biblioref">58</a></sup></span>.</p>
<p>Though BMI is a measure of ones weight for a given height it broadly provides a readout of ones fat mass (adipose tissue).</p>























































</div>
</div>
<h3>References</h3>
<div id="refs" class="references">
<div id="ref-WorldHealthOrganisation2018">
<p>1. World Health Organisation. <em>Factsheet: Obesity and overweight</em>. (2018).</p>
</div>
<div id="ref-Ng2014">
<p>2. Ng, M. <em>et al.</em> Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. <em>Lancet (London, England)</em> <strong>384</strong>, 766–781 (2014).</p>
</div>
<div id="ref-Abarca-Gomez2017">
<p>4. Abarca-Gómez, L. <em>et al.</em> Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128&amp;#xb7;9 million children, adolescents, and adults. <em>The Lancet</em> <strong>390</strong>, 2627–2642 (2017).</p>
</div>
<div id="ref-Stanaway2018">
<p>5. Stanaway, J. D. <em>et al.</em> Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Stu. <em>The Lancet</em> <strong>392</strong>, 1923–1994 (2018).</p>
</div>
<div id="ref-Ritchie2019">
<p>6. Ritchie, H. &amp; Roser, M. Obesity. Published online at OurWorldInData.org. Retrieved from: ’https://ourworldindata.org/obesity’ [Online Resource] 05/12/2019. (2019).</p>
</div>
<div id="ref-Frayn2003">
<p>7. Frayn, K. N., Karpe, F., Fielding, B. A., Macdonald, I. A. &amp; Coppack, S. W. Integrative physiology of human adipose tissue. <em>International Journal of Obesity</em> <strong>27</strong>, 875–888 (2003).</p>
</div>
<div id="ref-Cohen2016">
<p>8. Cohen, P. &amp; Spiegelman, B. M. Cell biology of fat storage. <em>Molecular biology of the cell</em> <strong>27</strong>, 2523–2527 (2016).</p>
</div>
<div id="ref-Luo2016">
<p>9. Luo, L. &amp; Liu, M. Adipose tissue in control of metabolism. <em>Journal of Endocrinology</em> <strong>231</strong>, R77–R99 (2016).</p>
</div>
<div id="ref-Kershaw2004">
<p>10. Kershaw, E. E. &amp; Flier, J. S. Adipose Tissue as an Endocrine Organ. <em>The Journal of Clinical Endocrinology &amp; Metabolism</em> <strong>89</strong>, 2548–2556 (2004).</p>
</div>
<div id="ref-Dahlman2010">
<p>11. Dahlman, I. &amp; Arner, P. Chapter 3 - Genetics of Adipose Tissue Biology. in <em>Genes and obesity</em> (eds. Bouchard, C. B. T. P. in M. B. &amp; Science, T.) <strong>94</strong>, 39–74 (Academic Press, 2010).</p>
</div>
<div id="ref-Galgani2008">
<p>12. Galgani, J. &amp; Ravussin, E. Energy metabolism, fuel selection and body weight regulation. <em>International journal of obesity (2005)</em> <strong>32 Suppl 7</strong>, S109–S119 (2008).</p>
</div>
<div id="ref-Amitani2013">
<p>13. Amitani, M., Asakawa, A., Amitani, H. &amp; Inui, A. The role of leptin in the control of insulin-glucose axis. <strong>7</strong>, 51 (2013).</p>
</div>
<div id="ref-Gray2007">
<p>14. Gray, S. L. &amp; Vidal-Puig, A. J. Adipose Tissue Expandability in the Maintenance of Metabolic Homeostasis. <em>Nutrition Reviews</em> <strong>65</strong>, S7–S12 (2007).</p>
</div>
<div id="ref-Cannon2004">
<p>15. Cannon, B. &amp; Nedergaard, J. A. N. Brown Adipose Tissue: Function and Physiological Significance. <em>Physiological Reviews</em> <strong>84</strong>, 277–359 (2004).</p>
</div>
<div id="ref-Lee2014">
<p>16. Lee, J.-E. &amp; Ge, K. Transcriptional and epigenetic regulation of PPAR<span class="math inline">\(\gamma\)</span> expression during adipogenesis. <em>Cell &amp; Bioscience</em> <strong>4</strong>, 29 (2014).</p>
</div>
<div id="ref-Schreiber2019">
<p>17. Schreiber, R., Xie, H. &amp; Schweiger, M. Of mice and men: The physiological role of adipose triglyceride lipase (ATGL). <em>Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids</em> <strong>1864</strong>, 880–899 (2019).</p>
</div>
<div id="ref-Lehr2012">
<p>18. Lehr, S., Hartwig, S. &amp; Sell, H. Adipokines: A treasure trove for the discovery of biomarkers for metabolic disorders. <em>PROTEOMICS – Clinical Applications</em> <strong>6</strong>, 91–101 (2012).</p>
</div>
<div id="ref-Fasshauer2015">
<p>19. Fasshauer, M. &amp; Blüher, M. Adipokines in health and disease. <em>Trends in Pharmacological Sciences</em> <strong>36</strong>, 461–470 (2015).</p>
</div>
<div id="ref-Bluher2013">
<p>20. Blüher, M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. <em>Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism</em> <strong>27</strong>, 163–177 (2013).</p>
</div>
<div id="ref-Bluher2015">
<p>21. Blüher, M. &amp; Mantzoros, C. S. From leptin to other adipokines in health and disease: Facts and expectations at the beginning of the 21st century. <em>Metabolism</em> <strong>64</strong>, 131–145 (2015).</p>
</div>
<div id="ref-Pan2018">
<p>22. Pan, W. W. &amp; Myers, M. G. Leptin and the maintenance of elevated body weight. <em>Nature Reviews Neuroscience</em> <strong>19</strong>, 95–105 (2018).</p>
</div>
<div id="ref-Ahn2019">
<p>23. Ahn, J., Wu, H. &amp; Lee, K. Integrative Analysis Revealing Human Adipose-Specific Genes and Consolidating Obesity Loci. <em>Scientific Reports</em> <strong>9</strong>, 3087 (2019).</p>
</div>
<div id="ref-Achari2017">
<p>24. Achari, E. A. &amp; Jain, K. S. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. <strong>18</strong>, (2017).</p>
</div>
<div id="ref-Lefterova2009">
<p>25. Lefterova, M. I. &amp; Lazar, M. A. New developments in adipogenesis. <em>Trends in Endocrinology &amp; Metabolism</em> <strong>20</strong>, 107–114 (2009).</p>
</div>
<div id="ref-Ma2013a">
<p>26. Ma, R. C. W. &amp; Chan, J. C. N. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. <em>Annals of the New York Academy of Sciences</em> <strong>1281</strong>, 64–91 (2013).</p>
</div>
<div id="ref-Elsworth2018">
<p>27. Elsworth, B. <em>et al.</em> MELODI: Mining Enriched Literature Objects to Derive Intermediates. <em>International Journal of Epidemiology</em> <strong>47</strong>, 369–379 (2018).</p>
</div>
<div id="ref-Pischon2008">
<p>28. Pischon, T. <em>et al.</em> General and Abdominal Adiposity and Risk of Death in Europe. <em>New England Journal of Medicine</em> <strong>359</strong>, 2105–2120 (2008).</p>
</div>
<div id="ref-Pasco2012">
<p>31. Pasco, J. A., Nicholson, G. C., Brennan, S. L. &amp; Kotowicz, M. A. Prevalence of obesity and the relationship between the body mass index and body fat: Cross-sectional, population-based data. <em>PLoS ONE</em> <strong>7</strong>, (2012).</p>
</div>
<div id="ref-Flegal2013">
<p>32. Flegal, K. M., Kit, B. K., Orpana, H. &amp; Graubard, B. I. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. <em>JAMA</em> <strong>309</strong>, 71–82 (2013).</p>
</div>
<div id="ref-Elagizi2018">
<p>34. Elagizi, A. <em>et al.</em> An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases. <em>Progress in Cardiovascular Diseases</em> <strong>61</strong>, 142–150 (2018).</p>
</div>
<div id="ref-Banack2013">
<p>35. Banack, H. R. &amp; Kaufman, J. S. The ‘Obesity Paradox’ Explained. <em>Epidemiology</em> <strong>24</strong>, (2013).</p>
</div>
<div id="ref-Khan2018">
<p>37. Khan, S. S. <em>et al.</em> Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity. <em>JAMA Cardiology</em> <strong>3</strong>, 280–287 (2018).</p>
</div>
<div id="ref-Sahakyan2015">
<p>38. Sahakyan, K. R. <em>et al.</em> Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality. <em>Annals of internal medicine</em> <strong>163</strong>, 827–835 (2015).</p>
</div>
<div id="ref-Hamer2017">
<p>39. Hamer, M., O’Donovan, G., Stensel, D. &amp; Stamatakis, E. Normal-Weight Central Obesity and Risk for Mortality. <em>Annals of Internal Medicine</em> <strong>166</strong>, 917–918 (2017).</p>
</div>
<div id="ref-WorldHealthOrganisation2008">
<p>40. World Health Organisation. <em>Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation</em>. (WHO, 2008).</p>
</div>
<div id="ref-Collaboration2009">
<p>41. Prospective Studies Collaboration <em>et al.</em> Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. <em>Lancet (London, England)</em> <strong>373</strong>, 1083–1096 (2009).</p>
</div>
<div id="ref-WorldHealthOrganisation2000">
<p>42. World Health Organisation. <em>Obesity : preventing and managing the global epidemic : report of a WHO consultation</em>. (WHO, 2000).</p>
</div>
<div id="ref-Dobbelsteyn2001">
<p>43. Dobbelsteyn, C. J., Joffres, M. R., MacLean, D. R., Flowerdew, G. &amp; Group, T. C. H. H. S. R. A comparative evaluation of waist circumference, waist-to-hip ratio and body mass index as indicators of cardiovascular risk factors. The Canadian Heart Health Surveys. <em>International Journal of Obesity</em> <strong>25</strong>, 652–661 (2001).</p>
</div>
<div id="ref-Rost2018">
<p>46. Rost, S. <em>et al.</em> New indexes of body fat distribution and sex-specific risk of total and cause-specific mortality: a prospective cohort study. <em>BMC Public Health</em> <strong>18</strong>, 427 (2018).</p>
</div>
<div id="ref-Lee2018">
<p>47. Lee, D. H. <em>et al.</em> Predicted lean body mass, fat mass, and all cause and cause specific mortality in men: prospective US cohort study. <em>BMJ</em> <strong>362</strong>, k2575 (2018).</p>
</div>
<div id="ref-Jo2018">
<p>49. Jo, A. &amp; Mainous III, A. G. Informational value of percent body fat with body mass index for the risk of abnormal blood glucose: a nationally representative cross-sectional study. <em>BMJ Open</em> <strong>8</strong>, e019200 (2018).</p>
</div>
<div id="ref-Albuquerque2017">
<p>50. Albuquerque, D., Nóbrega, C., Manco, L. &amp; Padez, C. The contribution of genetics and environment to obesity. <em>British Medical Bulletin</em> <strong>123</strong>, 159–173 (2017).</p>
</div>
<div id="ref-Loos2018">
<p>52. Loos, R. J. The genetics of adiposity. <em>Current opinion in genetics &amp; development</em> <strong>50</strong>, 86–95 (2018).</p>
</div>
<div id="ref-Sudlow2015">
<p>53. Sudlow, C. <em>et al.</em> UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. <em>PLOS Medicine</em> <strong>12</strong>, e1001779 (2015).</p>
</div>
<div id="ref-DaveySmith2003">
<p>54. Davey Smith, G. &amp; Ebrahim, S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?*. <em>International Journal of Epidemiology</em> <strong>32</strong>, 1–22 (2003).</p>
</div>
<div id="ref-Davies2018">
<p>55. Davies, N. M., Holmes, M. V. &amp; Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. <em>BMJ</em> <strong>362</strong>, k601 (2018).</p>
</div>
<div id="ref-Burgess2015">
<p>56. Burgess, S., Timpson, N. J., Ebrahim, S. &amp; Davey Smith, G. Mendelian randomization: where are we now and where are we going? <em>International Journal of Epidemiology</em> <strong>44</strong>, 379–388 (2015).</p>
</div>
<div id="ref-Bowden2019">
<p>57. Bowden, J. &amp; Holmes, M. V. Meta-analysis and Mendelian randomization: A review. <em>Research Synthesis Methods</em> <strong>0</strong>, (2019).</p>
</div>
<div id="ref-Pouliot1994">
<p>58. Pouliot, M.-C. <em>et al.</em> Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. <em>The American Journal of Cardiology</em> <strong>73</strong>, 460–468 (1994).</p>
</div>
<div id="ref-Bray2004">
<p>59. Bray, G. A. Medical Consequences of Obesity. <em>The Journal of Clinical Endocrinology &amp; Metabolism</em> <strong>89</strong>, 2583–2589 (2004).</p>
</div>
<div id="ref-Haslam2005">
<p>60. Haslam, D. W. &amp; James, W. P. T. Obesity. <em>The Lancet</em> <strong>366</strong>, 1197–1209 (2005).</p>
</div>
<div id="ref-Bhaskaran2014">
<p>61. Bhaskaran, K. <em>et al.</em> Body-mass index and risk of 22 specific cancers: a population-based cohort study of 524 million UK adults. <em>Lancet (London, England)</em> <strong>384</strong>, 755–765 (2014).</p>
</div>
<div id="ref-Jayedi2018">
<p>62. Jayedi, A., Rashidy-Pour, A., Khorshidi, M. &amp; Shab-Bidar, S. Body mass index, abdominal adiposity, weight gain and risk of developing hypertension: a systematic review and dose–response meta-analysis of more than 2.3 million participants. <em>Obesity Reviews</em> <strong>19</strong>, 654–667 (2018).</p>
</div>
<div id="ref-Dagfinn2016">
<p>63. Dagfinn, A. <em>et al.</em> Body Mass Index, Abdominal Fatness, and Heart Failure Incidence and Mortality. <em>Circulation</em> <strong>133</strong>, 639–649 (2016).</p>
</div>
<div id="ref-Beydoun2008">
<p>64. Beydoun, M. A., Beydoun, H. A. &amp; Wang, Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. <em>Obesity reviews : an official journal of the International Association for the Study of Obesity</em> <strong>9</strong>, 204–218 (2008).</p>
</div>
<div id="ref-Poulain2006">
<p>65. Poulain, M. <em>et al.</em> The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. <em>CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne</em> <strong>174</strong>, 1293–1299 (2006).</p>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="index.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="chapter2.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": [["thesis.pdf", "PDF"], ["thesis.epub", "EPUB"], ["thesis.docx", "Word"]],
"toc": {
"collapse": "section"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
